4-(cyclopropylmethyl)-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(cyclopropylmethyl)-1H-pyrazole
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: NLMOBTBCGICDMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS HÉTÉROARYLE, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI, ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD

  公开号：WO2019155468A1

  公开（公告）日：2019-08-15

  Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9). Formula: (I),(IA)

  本文提供了杂环芳基化合物，例如，式I或IA的化合物，以及其药物组成物。本文还提供了它们用于治疗、改善或预防由酪蛋白激酶1（CK1）、白细胞介素-1受体相关激酶（IRAK1）或细胞周期依赖性激酶9（CDK9）介导的一种或多种疾病、疾病或症状的方法。公式：（I），（IA）
• [EN] TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2022115384A1

  公开（公告）日：2022-06-02

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本文提供了公式(I)的化合物或其药学上可接受的盐，包括本文所描述的化合物(包括其药学上可接受的盐)的制药组合物和合成方法。本文还提供了使用公式(I)的化合物或其药学上可接受的盐治疗疾病和/或病症的方法。
• HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：US20200383984A1

  公开（公告）日：2020-12-10

  Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9). Formula: (I),(IA)
• TRICYCLIC COMPOUNDS
  申请人：ALIGOS THERAPEUTICS, INC.

  公开号：US20220169650A1

  公开（公告）日：2022-06-02

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.